{"disease":{"id":"gastro-enteropancreatic-neuroendocrine-tumor","name":"gastro enteropancreatic neuroendocrine tumor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT02630654","title":"Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs","phase":"","overall_status":"COMPLETED","enrollment_count":404,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT04986085","title":"Nutrition in Gastroenteropancreatic Neuroendocrine Tumor","phase":"","overall_status":"COMPLETED","enrollment_count":399,"lead_sponsor_name":"Grupo Espanol de Tumores Neuroendocrinos","has_results":true},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT06155318","title":"68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT05636618","title":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Perspective Therapeutics","has_results":false},{"nct_id":"NCT07165886","title":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":243,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT06784752","title":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03972488","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":226,"lead_sponsor_name":"Advanced Accelerator Applications","has_results":true},{"nct_id":"NCT02709889","title":"Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":200,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04727723","title":"Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":164,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02948946","title":"Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT02730104","title":"Community-based Neuroendocrine Tumor (NET) Research Study","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT06256705","title":"Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06091748","title":"Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT03457844","title":"A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT04086485","title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04090034","title":"Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Methodist Health System","has_results":false},{"nct_id":"NCT04852679","title":"Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Ipsen","has_results":true},{"nct_id":"NCT04524442","title":"Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Advanced Accelerator Applications","has_results":true},{"nct_id":"NCT03980925","title":"Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Grupo Espanol de Tumores Neuroendocrinos","has_results":true},{"nct_id":"NCT03600233","title":"Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"TaiRx, Inc.","has_results":false},{"nct_id":"NCT03220217","title":"To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Ipsen","has_results":true},{"nct_id":"NCT03017690","title":"Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03043664","title":"Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Duke University","has_results":true},{"nct_id":"NCT06253897","title":"A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT01423734","title":"The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT02608203","title":"[68 Ga]-DOTANOC PET/CT in GEP-NETs","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT04711135","title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":11,"lead_sponsor_name":"Advanced Accelerator Applications","has_results":true},{"nct_id":"NCT03042780","title":"FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT05987176","title":"Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT04915144","title":"177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT04614766","title":"A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"David Bushnell","has_results":false}],"total":33},"guidelines":[],"source":"Drug Landscape verified database"}